ClinicalTrials.gg
CompletedNCT03248232Updated Oct 2, 2018

Assessments of Thrombus Formation in TAVI

An observational study in Aortic Valve Stenosis and Heart Valve Diseases, sponsored by Kumamoto University. Completed at 1 site in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Kumamoto University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
23
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Aortic Valve Stenosis with a site in Japan — 4 open to participants now, 7 under way, none of them phase 3. Aortic Valve Stenosis · Japan.

Started
2017
the only one that year
Observational
4 of 19
1 open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
Kumamoto University

Among the 19 studies in Aortic Valve Stenosis with a site in Japan, this one is the only one that started in 2017, is one of 4 observational ones, and was the 15th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

4 of the 19 studies in Aortic Valve Stenosis with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Aortic Valve Stenosis with a site in Japan, or all of them as a file.
02

Study summary

Transcatheter aortic valve implantation (TAVI) is well established, and can improve clinical outcomes of patients with severe aortic valve stenosis (AS) who are inoperable or have high surgical risk. Although the rates of periprocedural bleeding events are lower in TAVI compared to those in surgical aortic valve replacement, those in TAVI still remains high. In addition, current guideline recommended the dual antiplatelet (DAPT), clopidogrel plus aspirin, for a 3- to 6-month period after TAVI, however no evidences supports this approach. The antithrombotic regimen in patients undergoing TAVI is needed to be established.

To establish the antithrombotic regimen in patients undergoing TAVI,

  1. the investigators assess the changes in platelet thrombus formation and white thrombus formation in patients undergoing TAVI measured by Total Thrombus Formation Analysis System (T-TAS).
  2. the investigators analyze plasma microRNAs, and shear stress by using computational fluid dynamics (CFD) to clarify the mechanistic factors regarding those changes.
03

Conditions studied

  • Aortic Valve Stenosis
  • Heart Valve Diseases

Keywords

  • Transcatheter aortic valve implantation
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with severe symptomatic aortic valve stenosis, undergoing transcatheter aortic valve implantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • twenty years and older
  • with the of the patient or support person in case of disability at baseline (patient intubated and ventilated)

Exclusion criteria

Exclusion Criteria:

  • withdrawn the
  • patients with trans-apical approach
  • critical illness condition (severe infectious disease, cancer, severe bleeding disorder)
  • transition to the surgical AVR
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
23 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Changes in T-TAS parameters (AR-chip, PL-chip) during TAVI

    To measure the thrombus formation area under the curve for AR-chip (AR10-AUC30), and PL-chip (PL24-AUC10) before and after TAVI.

    Time frame: pre-, day 2, day 7, 1 month after device implantation

Secondary outcomes

  1. Changes in shear stress analyzed by using CFD analysis of contrast-enhanced CT

    To measure the shear stress of aortic valve and aorta before and after TAVI by using CFD analysis of contrast-enhanced computed tomography (CT).

    Time frame: pre-, day 7 after device implantation

  2. Changes in von Willebrand factor multimer decrease

    To measure the von Willebrand factor multimer decrease by using electrophoresis

    Time frame: pre-, day 2 after device implantation

  3. Periprocedural complication, particularly, bleeding complication defined by VARC-2 criteria.

    Time frame: within 30 days after device implantation

Other outcomes

  1. Changes in plasma microRNAs

    To measure the expression of plasma microRNAs before and after TAVI by using qPCR.

    Time frame: pre-, day 2 after device implantation

07

Study locations

1 site
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
08

References and documents

Publications

  • Ishii M, Kaikita K, Mitsuse T, Nakanishi N, Oimatsu Y, Yamashita T, Nagamatsu S, Tabata N, Fujisue K, Sueta D, Takashio S, Arima Y, Sakamoto K, Yamamoto E, Tsujita K. Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation - The ATTRACTIVE-TTAS study. Int J Cardiol Heart Vasc. 2019 Mar 28;23:100346. doi: 10.1016/j.ijcha.2019.100346. eCollection 2019 Jun. PubMed 30976651 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Apr 2018, 8 months.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's 8 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2017
First posted
Aug 14, 2017
StartActual
Aug 1, 2017
Primary completionActual
Apr 30, 2018
CompletionActual
Jun 30, 2018
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03248232
Lead sponsor
Kumamoto University
Responsible party
Kenichi Tsujita, MD, PhD (Professor of Cardiovascular Medicine, Principal Investigator, Kumamoto University) — Principal investigator
First posted
Aug 14, 2017
Start date
Aug 1, 2017
Primary completion
Apr 30, 2018
Completion
Jun 30, 2018
Last update
Oct 2, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion